A little chain from an unusual place
MOTS-c is a peptide made from 16 amino acids. Its instructions come from mitochondrial DNA. Mitochondria help cells handle energy and have some DNA of their own.
The discovery paper linked MOTS-c with how cells and mice handled fuel. That's an interesting starting point. The important next step is asking what kind of experiment produced the excitement.
Mice gave researchers something to follow
In the original work, mice on a high-fat diet gained less weight and handled glucose better when given MOTS-c. Later exercise research found better physical performance in treated mice. Neither finding establishes a benefit from giving it to people.
The exercise paper also measured people's own MOTS-c around exercise. Watching a natural signal change is a different experiment from administering a preparation. The cell work makes that distinction even clearer.
A cell result is a clue
In cell experiments under metabolic stress, MOTS-c entered the nucleus, where the cell keeps its main DNA, and affected gene activity. Here, stress means conditions that challenge a cell's handling of fuel. It doesn't mean a tiring week.
That may help explain the interest in MOTS-c. It doesn't show that taking it repairs aging tissues or prevents disease. Those claims need evidence from treatment studies in people.
Back with the mouse findings, a possible explanation makes them worth studying. It doesn't turn them into a result about your health.
The missing safety evidence matters
There is no FDA-approved MOTS-c medicine. The FDA review found no published clinical studies giving MOTS-c to people. It also raised concerns about impurities and immune reactions, where the body's defenses react to a preparation. These are concerns, rather than a measured rate of harm in treated people.
In its written review for the July 2026 advisory meeting, FDA staff proposed not adding either MOTS-c free base or MOTS-c acetate to the 503A Bulks List. That list is one legal route for using bulk ingredients in compounding. MOTS-c isn't on it.
The FDA safety page, current as of April 22, 2026, lists MOTS-c among withdrawn nominations, outside the current Category 2 table. Withdrawal isn't clearance, Category 1 placement or permission to compound. The page gives no individual withdrawal date.
The wider picture is unfinished: promising experiments, missing human answers and unresolved safety questions. A prescription doesn't change those facts. The comparison puts that gap beside the very different evidence for semaglutide and NAD+.